James M. Gloor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James M. Gloor has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Mark D. Stegall
Mayo Clinic
5 shared publicationsM D Stegall
4 shared publicationsM. D. Stegall
Department of Surgery and Transplant Center
4 shared publicationsDonna J. Lager
3 shared publicationsF. G. Cosio
Division of Nephrology and Hypertension and Transplant Center, Department of Internal Medicine
3 shared publications- Jeffrey Lawrence Winters
Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA
3 shared publications
Latest Publications
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 65
ABO Incompatible (ABOiKTx) Vs Positive Crossmatch Kidney Transplants (+XMKTx): Does Differences in Capillaritis Correlate with Outcome?
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 65
ABO Incompatible (ABOiKTx) Vs Positive Crossmatch Kidney Transplants (+XMKTx): Does Differences in Capillaritis Correlate with Outcome?
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 177
Actual Five Year Outcomes of Positive Crossmatch Kidney Transplant Recipients and the Role of Class II DSA in Chronic Injury
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 177
Actual Five Year Outcomes of Positive Crossmatch Kidney Transplant Recipients and the Role of Class II DSA in Chronic Injury
- 16 March 2010
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 6 (5) , 297-306
Sensitized renal transplant recipients: current protocols and future directions
The identification of suitable donor kidneys for transplant candidates with high levels of circulating antibodies against human leukocyte antigen (HLA) is a major challenge and results in prolonged waiting times for transplantation. Technological advances in antibody characterization have permitted a more comprehensive assessment of anti-HLA antibody activity, as well as providing new insights into the clinical effect of HLA antibody class and specificity. Protocols have been developed that enable successful transplantation in patients with donor-specific antibodies (anti-HLA antibodies reactive against their donors). These protocols provide satisfactory early to intermediate-term allograft survival, and constitute an important advance in transplantation. Nevertheless, acute antibody-mediated rejection (AMR) remains a significant challenge, occurring in 20-50% of antibody-incompatible kidney transplantations. Although therapy directed toward lowering donor-specific antibody activity seems to be successful in reversing acute AMR, this condition still has an important negative impact on allograft survival. In addition, subclinical AMR seems to complicate a substantial proportion of positive-crossmatch transplantations even in the absence of allograft dysfunction, and may result in chronic histological abnormalities and shortened allograft function. New interventions for preventing acute AMR, such as anti-C5 antibody-mediated complement blockade and proteasome inhibitor-mediated plasma cell depletion, are promising therapeutic avenues currently under investigation.
- 16 March 2010
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 6 (5) , 297-306
Sensitized renal transplant recipients: current protocols and future directions
The identification of suitable donor kidneys for transplant candidates with high levels of circulating antibodies against human leukocyte antigen (HLA) is a major challenge and results in prolonged waiting times for transplantation. Technological advances in antibody characterization have permitted a more comprehensive assessment of anti-HLA antibody activity, as well as providing new insights into the clinical effect of HLA antibody class and specificity. Protocols have been developed that enable successful transplantation in patients with donor-specific antibodies (anti-HLA antibodies reactive against their donors). These protocols provide satisfactory early to intermediate-term allograft survival, and constitute an important advance in transplantation. Nevertheless, acute antibody-mediated rejection (AMR) remains a significant challenge, occurring in 20-50% of antibody-incompatible kidney transplantations. Although therapy directed toward lowering donor-specific antibody activity seems to be successful in reversing acute AMR, this condition still has an important negative impact on allograft survival. In addition, subclinical AMR seems to complicate a substantial proportion of positive-crossmatch transplantations even in the absence of allograft dysfunction, and may result in chronic histological abnormalities and shortened allograft function. New interventions for preventing acute AMR, such as anti-C5 antibody-mediated complement blockade and proteasome inhibitor-mediated plasma cell depletion, are promising therapeutic avenues currently under investigation.
- Open Access
- 16 February 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (3) , 582-589
Baseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation
- 16 February 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (3) , 582-589
Open AccessBaseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation
- Open Access
- 1 July 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (7) , 1367-1373
The Spectrum of Antibody-Mediated Renal Allograft Injury: Implications for Treatment
- 1 July 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (7) , 1367-1373
Open AccessThe Spectrum of Antibody-Mediated Renal Allograft Injury: Implications for Treatment
- 1 November 2007
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 16 (6) , 529-534
ABO incompatible kidney transplantation
Although ABO incompatible kidney transplantation is increasingly recognized as effective, the procedure is still evolving. The purpose of this review is to summarize recent advances in this area. Short to intermediate-term outcome appears good, although long-term results are still preliminary. Pretransplant risk stratification based on antidonor antibody titer may be of limited value. Splenectomy, previously reported to be an important component of ABO incompatible transplantation, appears to be avoidable under many circumstances. The wider implementation of A2 blood group incompatible transplantation shortens waiting time for deceased donor transplantation of blood group B recipients without significantly disadvantaging others. The diagnosis of acute humoral rejection has become clearer following the recognition that C4d deposition commonly occurs in well functioning ABO incompatible allografts. The long-term implications of acute humoral rejection appear substantial even following successful acute therapy, with a significant percentage of patients developing chronic humoral rejection manifested as transplant glomerulopathy. Finally, although ABO incompatible transplantation entails increased expense, when compared with maintenance dialysis and taking into account the health related quality of life benefits of a successful transplant, it is clearly cost effective. ABO incompatible kidney transplantation is an effective therapy, and will become more widely implemented in the future.
- 1 November 2007
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 16 (6) , 529-534
ABO incompatible kidney transplantation
Although ABO incompatible kidney transplantation is increasingly recognized as effective, the procedure is still evolving. The purpose of this review is to summarize recent advances in this area. Short to intermediate-term outcome appears good, although long-term results are still preliminary. Pretransplant risk stratification based on antidonor antibody titer may be of limited value. Splenectomy, previously reported to be an important component of ABO incompatible transplantation, appears to be avoidable under many circumstances. The wider implementation of A2 blood group incompatible transplantation shortens waiting time for deceased donor transplantation of blood group B recipients without significantly disadvantaging others. The diagnosis of acute humoral rejection has become clearer following the recognition that C4d deposition commonly occurs in well functioning ABO incompatible allografts. The long-term implications of acute humoral rejection appear substantial even following successful acute therapy, with a significant percentage of patients developing chronic humoral rejection manifested as transplant glomerulopathy. Finally, although ABO incompatible transplantation entails increased expense, when compared with maintenance dialysis and taking into account the health related quality of life benefits of a successful transplant, it is clearly cost effective. ABO incompatible kidney transplantation is an effective therapy, and will become more widely implemented in the future.
- 27 July 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (2) , 258-264
The Effect of Antithymocyte Globulin on Anti–Human Leukocyte Antigen Antibody Detection Assays
Background. We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte antigen (HLA) antibody assays. Methods. We tested sera from six in vivo ATG-treated kidney transplant patients after measuring serum concentrations, as well as six nonsensitized sera with ATG added in vitro. T- and B-cell complement-dependent cytotoxicity (CDC), flow cytometric (FXM), and solid-phase HLA class I and II assays based on antigen-coated microspheres and enzyme-linked immunosorbent assay (ELISA) were studied. Sera were then retested after treatment to remove ATG. Results. We found that ATG affects test results differently depending on whether sera is obtained from in vivo treated patients or added in vitro. In vitro treated sera produced ATG concentration-dependent positive results for T/B CDC, FXM, and flow bead testing for HLA I/II, while the ELISA-based assay was unaffected. In vivo treated sera from ATG-treated patients produced positive test results for T CDC and T/B FXM, while the B-cell CDC crossmatch remained negative. Solid phase assays were minimally affected using in vivo treated sera. After ATG extraction, all tests became negative. Conclusion. We conclude that ATG produces positive results in anti-HLA antibody testing, and treatment to remove ATG abolishes this effect. This treatment allows ATG-treated patients to be monitored for anti-HLA antibodies.
- 27 July 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (2) , 258-264
The Effect of Antithymocyte Globulin on Anti–Human Leukocyte Antigen Antibody Detection Assays
Background. We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte antigen (HLA) antibody assays. Methods. We tested sera from six in vivo ATG-treated kidney transplant patients after measuring serum concentrations, as well as six nonsensitized sera with ATG added in vitro. T- and B-cell complement-dependent cytotoxicity (CDC), flow cytometric (FXM), and solid-phase HLA class I and II assays based on antigen-coated microspheres and enzyme-linked immunosorbent assay (ELISA) were studied. Sera were then retested after treatment to remove ATG. Results. We found that ATG affects test results differently depending on whether sera is obtained from in vivo treated patients or added in vitro. In vitro treated sera produced ATG concentration-dependent positive results for T/B CDC, FXM, and flow bead testing for HLA I/II, while the ELISA-based assay was unaffected. In vivo treated sera from ATG-treated patients produced positive test results for T CDC and T/B FXM, while the B-cell CDC crossmatch remained negative. Solid phase assays were minimally affected using in vivo treated sera. After ATG extraction, all tests became negative. Conclusion. We conclude that ATG produces positive results in anti-HLA antibody testing, and treatment to remove ATG abolishes this effect. This treatment allows ATG-treated patients to be monitored for anti-HLA antibodies.
- Top Cited PapersOpen Access
- 3 July 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (9) , 2124-2132
Transplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody
- 3 July 2007
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (9) , 2124-2132
Top Cited PapersOpen AccessTransplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody
- Open Access
- 19 June 2006
- Published by Elsevier in American Journal of Transplantation
- Vol. 6 (8) , 1841-1847
Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation
- 19 June 2006
- Published by Elsevier in American Journal of Transplantation
- Vol. 6 (8) , 1841-1847
Open AccessHistologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation
- 1 December 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (11) , 1572-1577
A Comparison of Splenectomy versus Intensive Posttransplant Antidonor Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation
Although most protocols for ABO-incompatible kidney transplantation have employed splenectomy, its utility is unproven. The aim of the current study was to compare the outcomes of ABO-incompatible living donor kidney transplantation with splenectomy versus a protocol involving intensive posttransplant antibody monitoring to maintain low levels of antiblood group antibody. We retrospectively studied all ABO-incompatible living donor kidney transplants at our institution between September 1999 and November 2004 (n=34). Prior to May 2003, all patients were included in a protocol involving pretransplant plasmapheresis and splenectomy at the time of transplant (n=23). After May 2003, splenectomy was not performed and a protocol that involved pretransplant anti-CD20 antibody and a more intensive posttransplant plasmapheresis regiment aimed at maintaining low levels of antiblood group antibody during the first 2 weeks following transplantation was utilized (n=11). Patient and graft survival was similar in the two groups. Humoral rejection occurred in 18% nonsplenectomized and 30% of splenectomized patients (P=0.68). Humoral rejection correlated with the baseline antibody titer in both groups. Individuals with elevated baseline antibody titer (≥1:256) appear to be at high risk for humoral rejection regardless of protocol used. Antiblood group antibody levels 3 and 12 months after transplantation were similar in both groups. Splenectomy is not essential for successful ABO-incompatible kidney transplantation, although individuals with high baseline antidonor blood group antibody titers are at high risk for humoral rejection. The use of intensive posttransplant monitoring may help prevent antibody-mediated graft damage.
- 1 December 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (11) , 1572-1577
A Comparison of Splenectomy versus Intensive Posttransplant Antidonor Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation
Although most protocols for ABO-incompatible kidney transplantation have employed splenectomy, its utility is unproven. The aim of the current study was to compare the outcomes of ABO-incompatible living donor kidney transplantation with splenectomy versus a protocol involving intensive posttransplant antibody monitoring to maintain low levels of antiblood group antibody. We retrospectively studied all ABO-incompatible living donor kidney transplants at our institution between September 1999 and November 2004 (n=34). Prior to May 2003, all patients were included in a protocol involving pretransplant plasmapheresis and splenectomy at the time of transplant (n=23). After May 2003, splenectomy was not performed and a protocol that involved pretransplant anti-CD20 antibody and a more intensive posttransplant plasmapheresis regiment aimed at maintaining low levels of antiblood group antibody during the first 2 weeks following transplantation was utilized (n=11). Patient and graft survival was similar in the two groups. Humoral rejection occurred in 18% nonsplenectomized and 30% of splenectomized patients (P=0.68). Humoral rejection correlated with the baseline antibody titer in both groups. Individuals with elevated baseline antibody titer (≥1:256) appear to be at high risk for humoral rejection regardless of protocol used. Antiblood group antibody levels 3 and 12 months after transplantation were similar in both groups. Splenectomy is not essential for successful ABO-incompatible kidney transplantation, although individuals with high baseline antidonor blood group antibody titers are at high risk for humoral rejection. The use of intensive posttransplant monitoring may help prevent antibody-mediated graft damage.